Skip to main content
padlock icon - secure page this page is secure

Regulation of connexin 43 and microRNA expression via β2-adrenoceptor signaling in 1321N1 astrocytoma cells

Buy Article:

$42.00 + tax (Refund Policy)

Connexin 43 (Cx43) is the main gap junction protein in astrocytes and exerts the same effects on growth inhibition in astrocytoma and glioma as microRNA146a (miR146a) in glioma. β2adrenergic receptor (AR) signaling modulates Cx43 expression in myocytes via components downstream of protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). However, it remains to be elucidated how expression of Cx43 is modulated in astrocytes. In the present study, 1321N1 astrocytoma cells were treated with β2AR signaling agents in order to evaluate the expression of Cx43 and miRNAs. RNA and protein were extracted from the cells for use in reverse transcriptionquantitative polymerase chain reaction and western blot analysis, respectively. The results revealed that clenbuterol increased miR146a level and upregulated Cx43 expression via cAMP/PKA at the mRNA and protein level. Preinhibition of adenyl cyclase decreased expression of Cx43 and miR146a. PKA activation and overexpression of miR146a in A1321N1 cells increased the expression of Cx43. β2AR stimulation and 6Bnz, a PKA activator, suppressed oncomiRs miR155 and miR27a, while 8(4chlorophenylthio)2'Omethyladenosine3',5'cyclic monophosphate, an Epac activator, increased their levels. The current findings demonstrated that β2AR signaling has growth inhibitory effects via modulation of the cAMP/PKA pathway in A1321N1 cells through increasing the expression level of Cx43 and miR146a as well as decreasing miR155 and miR27a levels. Thus, stimulation of the β2AR and PKA signaling pathway may be a useful approach for astrocytoma therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Department of Physiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad 6814993165, Iran 2: Department of Molecular Biology and Genetic Engineering, Stem Cell Technology Research Center, Tehran 1997775555, Iran 3: Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran 4: Department of Molecular Medicine, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran 1417743371, Iran 5: Department of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran 1417755469, Iran 6: Department of Medical Biotechnologies, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran 1417743371, Iran 7: Department of Neuroscience, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran 1417743371, Iran

Publication date: August 1, 2015

More about this publication?
  • Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more